UNSPSC 51112405: Procarbazine hydrochloride

This classification denotes an antineoplastic agent with the molecular formula C12H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH0NPH5ZX8, chemically known as p-toluamide, n-isopropyl-.alpha.- (2-methylhydrazino)-, monohydrochloride but more generally known as procarbazine hydrochloride, which bears US NIH Compound Identifier 4915. European Medicines Agency schedules Procarbazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15017MIG.

UNSPSC 51112405 Procarbazine hydrochloride is a Commodity code covering a specific chemotherapy agent used in cancer treatment protocols. State and local governments procure this pharmaceutical primarily through health and human services agencies, corrections departments, and public health systems that operate integrated medical facilities or pharmacy benefit programs. The recent activity under this code reflects a shift toward direct-to-manufacturer procurement models as alternatives to traditional pharmacy benefit manager and group purchasing organization channels, particularly for cost management and supply chain efficiency in government-sponsored health plans.

The Texas Health and Human Services Commission issued Request for Information No. HHS0017013 on April 3, 2026, to solicit vendor capabilities regarding direct-to-manufacturer prescription programs that would enable state agencies and self-insured employee health plans to bypass conventional pharmacy intermediaries. The RFI seeks detailed vendor experience with direct contracting, negotiated net pricing without rebates, and value-based or outcomes-based contracting models. This exploratory procurement mechanism indicates the state is gathering market intelligence to inform future formal RFP strategy rather than making immediate purchasing commitments; no award value, budget range, or final specifications have been identified at this stage. The response deadline was April 3, 2026, with no site visits, pre-bid meetings, or set-aside designations specified in the preliminary phase.